pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
925
stories
May 7, 26
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
onclive
May 7, 26
EGFR-Targeted Therapy Sequencing After Resistance in NSCLC
onclive
May 7, 26
HERIZON-GEA-01 Study Design, Geographic Distribution, and PD-L1 Testing Considerations
onclive
May 7, 26
Integrating Evidence and Identifying Future Research Needs in Metastatic Castration Sensitive Prostate Cancer (mCSPC)
onclive
May 7, 26
Evaluating Observational and Propensity Matched Studies in Metastatic Castration Sensitive Prostate Cancer (mCSPC)
onclive
May 7, 26
Reigniting Your Curiosity During Fellowship
onclive
May 7, 26
STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
stat
May 7, 26
Hospital shootings steadily increased since 2000
stat
May 7, 26
STAT+: Next-gen Duchenne drug from Entrada disappoints
stat
May 7, 26
STAT+: Color me skeptical: Drinking gold is not an ALS cure
stat
May 6, 26
MANEUVER Trial Underscores Potential Paradigm Shift Toward Targeted Approaches in TGCT
onclive
May 6, 26
STAT+: Oregon hospitals won’t outsource to national physician chain after all
stat
May 6, 26
Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma
onclive
May 6, 26
Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer
onclive
May 6, 26
Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLC
onclive
May 6, 26
Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma
onclive
May 6, 26
BeOne culls five cancer programs and an autoimmune Phase 2
endpoints
May 6, 26
Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
onclive
May 6, 26
Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma
onclive
May 6, 26
Dr Sznol on Biomarkers of Response in Metastatic Melanoma
onclive
May 6, 26
Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery
onclive
May 6, 26
STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’
stat
May 6, 26
STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
stat
May 6, 26
Avalo shares spike on skin drug data; BioNTech to cut staff
biopharma dive
May 6, 26
ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
onclive
May 6, 26
Disease Assessment and Mutational Testing in Progressive CLL
onclive
May 6, 26
Clinical Scenario Presentation and Treatment Approach for Progressive Disease
onclive
May 6, 26
Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC
onclive
May 6, 26
Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026
onclive
May 6, 26
CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
biopharma dive
← prev
page 28 of 31
next →
